Alpha-Conotoxin - alpha9_alpha10 nAChRs
α-芋螺毒素 - alpha9_alpha10 nAChR
基本信息
- 批准号:8145706
- 负责人:
- 金额:$ 24.78万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-07-01 至 2013-06-30
- 项目状态:已结题
- 来源:
- 关键词:AcetylcholineAdvanced DevelopmentAffinityAlzheimer&aposs DiseaseAmino Acid SubstitutionAmino AcidsAnti-Inflammatory AgentsAnti-inflammatoryBindingBinding ProteinsBinding SitesBiological AssayCellsChimera organismCognitionConotoxinDataDevelopmentDiseaseDrosophila acetylcholine receptor alpha-subunitDrug or chemical Tissue DistributionElectrophysiology (science)ElementsEnvironmentEpitopesFaceFailureFamilyFluorescent ProbesFundingGated Ion ChannelGrantImageImmuneImmune systemIndividualInflammatory ResponseInhibitory Concentration 50InvestigationIon ChannelLigand BindingLigandsMedicineModelingMolecularMolecular ProbesMolecular StructureMuscleMutateMutationNeurogliaNeuronsNicotinic ReceptorsPainParalysedParkinson DiseasePathway interactionsPeptide SynthesisPeptidesPerceptionPeripheralPharmaceutical PreparationsPhysiological ProcessesPlayPopulationPotassium ChannelPredispositionProcessProgress ReportsReporterResistanceRoleSchizophreniaSensorySeriesSiteSite-Directed MutagenesisSnake VenomsSodium ChannelSpecificityStructure-Activity RelationshipTestingTissuesToxinTranslatingVenomsWorkX-Ray CrystallographyXenopus oocytealpha Bungarotoxinalpha-Conotoxinanalogbasechronic paindisulfide bondimprovedmembermotor controlnerve injurynew therapeutic targetnovelpainful neuropathypeptide analogprogramsreceptorthree dimensional structuretwo-dimensionalvoltage
项目摘要
Nicotinic acetylcholine receptors (nAChRs) regulate critical physiological processes in the nervous and
immune systems. These receptors represent potential therapeutic targets for new medicines to treat
disorders of motor control (e.g., Parkinson's Disease), cognition (e.g., Alzheimer's Disease and schizophrenia), and sensory perception (e.g., chronic pain). Multiple subtypes of nAChRs exist, and different subtypes of these receptors underlie the pathophsyiology of various disease states. However, the ability to pharmacologically distinguish among these subtypes has been a problem. Conotoxins are unique peptides that not only are being used to overcome this problem but also serve as powerful probes for molecular
characterization of nAChRs. We will utilize a newly discovered conotoxin RgIA, which specifically targets the alpha9alpha10 subtype of nAChR, to probe the molecular structure of the receptor. This subtype has a highly restricted tissue distribution and was recently shown to participate in a molecular pathway of neuropathic pain (i.e., pain induced by nerve injury). We will identify the features of RgIA that are responsible for its selectivity and high affinity for alpha9alpha10 nAChRs. We will use this information to create a battery of ligands, including fluorescent ones, to study alpha9alpha10 nAChRs in their native tissue
environment.
We have also exploited conotoxins to uncover and delineate previously unrecognized binding sites on the nAChR. In this regard, Project I will continue to work closely with discovery aspects of the Program to further characterize conotoxins that act at novel sites of nAChRs. Such investigation will enable further mechanistic understanding of the nAChR in particular and is expected to translate to improved understanding of ligandgated
ion channels in general.
烟碱型乙酰胆碱受体(nAChR)调节神经和中枢神经系统中的关键生理过程,
免疫系统这些受体代表了新药治疗的潜在治疗靶点
运动控制障碍(例如,帕金森病)、认知(例如,阿尔茨海默病和精神分裂症)和感觉知觉(例如,慢性疼痛)。存在nAChR的多种亚型,并且这些受体的不同亚型是各种疾病状态的病理生理学的基础。然而,在这些亚型之间进行快速区分的能力一直是一个问题。芋螺毒素是一种独特的多肽,不仅可以用来克服这一问题,而且还可以作为分子生物学的强有力的探针。
nAChR的表征。我们将利用一种新发现的芋螺毒素RgIA,它专门针对nAChR的α 9 α 10亚型,探测受体的分子结构。该亚型具有高度限制的组织分布,并且最近显示参与神经性疼痛的分子途径(即,由神经损伤引起的疼痛)。我们将确定RgIA的特点,负责其选择性和高亲和力的α 9 α 10 nAChRs。我们将利用这些信息来创建一组配体,包括荧光配体,以研究天然组织中的α 9 α 10 nAChR
环境
我们还利用芋螺毒素来揭示和描绘以前未被识别的nAChR结合位点。在这方面,项目I将继续与该计划的发现方面密切合作,以进一步表征作用于nAChRs新位点的芋螺毒素。这样的研究将使进一步的机制,特别是了解nAChR,并有望转化为更好的理解配体化的
离子通道
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
J MICHAEL MCINTOSH其他文献
J MICHAEL MCINTOSH的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('J MICHAEL MCINTOSH', 18)}}的其他基金
Development and Application of Nicotinic Acetylcholine Receptor Targeted Peptides for Biomedical Research
烟碱乙酰胆碱受体靶向肽在生物医学研究中的开发及应用
- 批准号:
10550213 - 财政年份:2020
- 资助金额:
$ 24.78万 - 项目类别:
相似海外基金
ADVANCED DEVELOPMENT OF LQ A LIPOSOME-BASED SAPONIN-CONTAINING ADJUVANT FOR USE IN PANSARBECOVIRUS VACCINES
用于 Pansarbecovirus 疫苗的 LQ A 脂质体含皂苷佐剂的先进开发
- 批准号:
10935820 - 财政年份:2023
- 资助金额:
$ 24.78万 - 项目类别:
ADVANCED DEVELOPMENT OF BBT-059 AS A RADIATION MEDICAL COUNTERMEASURE FOR DOSING UP TO 48H POST EXPOSURE"
BBT-059 的先进开发,作为辐射医学对策,可在暴露后 48 小时内进行给药”
- 批准号:
10932514 - 财政年份:2023
- 资助金额:
$ 24.78万 - 项目类别:
Advanced Development of a Combined Shigella-ETEC Vaccine
志贺氏菌-ETEC 联合疫苗的先进开发
- 批准号:
10704845 - 财政年份:2023
- 资助金额:
$ 24.78万 - 项目类别:
Advanced development of composite gene delivery and CAR engineering systems
复合基因递送和CAR工程系统的先进开发
- 批准号:
10709085 - 财政年份:2023
- 资助金额:
$ 24.78万 - 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
- 批准号:
10409385 - 财政年份:2022
- 资助金额:
$ 24.78万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
- 批准号:
10710595 - 财政年份:2022
- 资助金额:
$ 24.78万 - 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
- 批准号:
10630975 - 财政年份:2022
- 资助金额:
$ 24.78万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE CANDIDATE FOR STAPHYLOCOCCUS AUREUS INFECTION
金黄色葡萄球菌感染候选疫苗的高级开发
- 批准号:
10710588 - 财政年份:2022
- 资助金额:
$ 24.78万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
- 批准号:
10788051 - 财政年份:2022
- 资助金额:
$ 24.78万 - 项目类别:














{{item.name}}会员




